Mes: agosto 2016

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed … Leer más

Bone. 2016 Aug;89:25-31. doi: 10.1016/j.bone.2016.05.003. Epub 2016 May 11. In conclusion, the use of SSRIs seems to accelerate postmenopausal bone loss in a dose-response manner. Associations between TCA and other antidepressant use and bone loss … Leer más

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70. doi: 10.1210/jc.2016-1801. Epub 2016 Jun 6 In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greater BMD increases at all measured skeletal sites and … Leer más

J Clin Endocrinol Metab. 2016 Aug;101(8):3105-13. doi: 10.1210/jc.2016-1559. Epub 2016 May 26. Sun exposure levels failed to provide adequate vitamin D, with approximately one-quarter of adolescents insufficient even at summer peak. Seasonal vitamin D deficiency … Leer más

Among hip fracture patients, publication of NICE guidance and availability of generic alendronic acid was temporally associated with increased prescribing and a significant decline in subsequent fractures.

LCN2 is an important catabolic adipokine in osteoblast and chondrocyte metabolism that is regulated by differentiation, inflammation and catabolic and anabolic stimuli, and LCN2 expression in chondrocytes is regulated in a paracrine manner after osteoblast … Leer más

BMI and the daily time spent on moderate PA were found to be correlated with femoral neck BMD in CF patients. The association between daily PA and biochemical markers of bone formation suggests that the … Leer más

We propose the use of AM inhibitors for the treatment of osteoporosis and other conditions leading to the loss of bone mass.